Copyright thehindubusinessline
Torrent Pharmaceuticals Ltd, the flagship company of Torrent Group reported a 30.5 per cent year-on-year rise in net profit that stood at ₹591 crore for the second quarter of the financial year 2025-26. During the quarter, the revenues of the company that operates in a single segment i.e. generic formulation business rose 14 per cent to ₹3,302 crore. The revenues from India at ₹1,820 crores were up by 12 per cent led by outperformance in focus therapies, while revenues from Brazil at ₹318 crores, were up by 21 per cent. US business revenues at ₹337 crores, were up by 26 per cent, while Germany revenues at ₹303 crores, were up by 5 per cent. In Germany, the growth was impacted due to supply disruption at a third party supplier. During the quarter, the R&D expenditure rose by 8 per cent y-o-y to ₹156 crore. Torrent has 21 brands in the Top 500 brands in Indian Pharmaceuticals Market, with 15 brands having more than ₹100 crores sales. The company said that its decision to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited has no impact on the results for the quarter and half year ended September 30, 2025. With regard to this acquisition, the parent company has received approval from Competition Commission of South Africa and Competition Commission of India (CCI) on September 22, 2025 and October 21, 2025 respectively. Torrent Pharmaceuticals is a specialty-focused company with an estimated 76 per cent of its revenues in India from chronic and sub-chronic therapies. It has presence in more than 50 countries and is ranked number one amongst the Indian pharma Companies in Brazil and Germany Published on November 7, 2025
